1. Home
  2. ALNY vs KEYS Comparison

ALNY vs KEYS Comparison

Compare ALNY & KEYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALNY
  • KEYS
  • Stock Information
  • Founded
  • ALNY 2002
  • KEYS 1939
  • Country
  • ALNY United States
  • KEYS United States
  • Employees
  • ALNY N/A
  • KEYS N/A
  • Industry
  • ALNY Biotechnology: Pharmaceutical Preparations
  • KEYS Industrial Machinery/Components
  • Sector
  • ALNY Health Care
  • KEYS Industrials
  • Exchange
  • ALNY Nasdaq
  • KEYS Nasdaq
  • Market Cap
  • ALNY 33.1B
  • KEYS 29.0B
  • IPO Year
  • ALNY 2004
  • KEYS N/A
  • Fundamental
  • Price
  • ALNY $245.44
  • KEYS $163.29
  • Analyst Decision
  • ALNY Buy
  • KEYS Buy
  • Analyst Count
  • ALNY 23
  • KEYS 10
  • Target Price
  • ALNY $298.59
  • KEYS $180.80
  • AVG Volume (30 Days)
  • ALNY 671.5K
  • KEYS 1.5M
  • Earning Date
  • ALNY 02-13-2025
  • KEYS 01-29-2025
  • Dividend Yield
  • ALNY N/A
  • KEYS N/A
  • EPS Growth
  • ALNY N/A
  • KEYS N/A
  • EPS
  • ALNY N/A
  • KEYS 3.51
  • Revenue
  • ALNY $2,094,795,000.00
  • KEYS $4,979,000,000.00
  • Revenue This Year
  • ALNY $25.14
  • KEYS $7.51
  • Revenue Next Year
  • ALNY $17.35
  • KEYS $6.86
  • P/E Ratio
  • ALNY N/A
  • KEYS $46.50
  • Revenue Growth
  • ALNY 21.54
  • KEYS N/A
  • 52 Week Low
  • ALNY $141.98
  • KEYS $119.72
  • 52 Week High
  • ALNY $304.39
  • KEYS $175.39
  • Technical
  • Relative Strength Index (RSI)
  • ALNY 43.56
  • KEYS 47.21
  • Support Level
  • ALNY $233.41
  • KEYS $158.82
  • Resistance Level
  • ALNY $249.58
  • KEYS $172.24
  • Average True Range (ATR)
  • ALNY 7.63
  • KEYS 3.56
  • MACD
  • ALNY -0.21
  • KEYS -1.48
  • Stochastic Oscillator
  • ALNY 48.68
  • KEYS 29.34

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

About KEYS Keysight Technologies Inc.

Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.

Share on Social Networks: